Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synbiotic 2000FORTE
- Development stage
- Unknown
- Lead developer
- MediPharm Labs
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Enteral
01
Overview
Synbiotic 2000FORTE is a high-potency synbiotic preparation comprising four probiotic lactic acid bacteria strains—*Lactobacillus plantarum* 2362, *Lactobacillus paracasei* subsp. *paracasei* F19, *Lactobacillus acidophilus* La5, and *Bifidobacterium animalis* subsp. *lactis* Bb12—and four bioactive prebiotic fibers: betaglucan, inulin, pectin, and resistant starch. Developed primarily for use in critically ill patients, it aims to modulate the gut microbiome, enhance the intestinal mucosal barrier, and reduce systemic inflammation. Clinical evidence suggests that its administration can significantly decrease the risk of sepsis, bloodstream infections, and ventilator-associated pneumonia (VAP), particularly in patients with severe trauma or those undergoing major surgical procedures like liver transplantation or pancreatoduodenectomy. The 'FORTE' version is distinguished by a higher concentration of probiotics (10^11 CFU per strain) compared to the standard Synbiotic 2000 formulation.
- Brand names
- Synbiotic 2000FORTESynbiotic2000FORTESynbiotic-2000FORTE
- Other names
- Synbiotic 2000 ForteSynbiotic2000 ForteSynbiotic-2000 Forte
Beyond the preview
Go deeper on Synbiotic 2000FORTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synbiotic 2000FORTE.